.
  • NIFTY 25,891.40 +22.80 (+0.09%)
  • SENSEX 84,556.40 +130.06 (+0.15%)
 
BSE
NSE

Thursday, October 23, 2025 , BSE Sensex : 84,556.40 84,556.40(0.15%) , Adani Ports : 1,452.45 1,452.45(-1.41%) , Asian Paints : 2,501.85 2,501.85(-0.26%) , Axis Bank : 1,259.40 1,259.40(1.90%) , Bajaj Finance : 1,094.20 1,094.20(0.69%) , Bajaj Finserv : 2,175.85 2,175.85(0.28%) , Bharat Electron : 418.50 418.50(0.22%) , Bharti Airtel : 2,008.35 2,008.35(-1.71%) , Eternal Ltd : 328.30 328.30(-2.88%) , HCL Technologies : 1,524.05 1,524.05(2.43%) , HDFC Bank : 1,008.95 1,008.95(0.16%) , Hind. Unilever : 2,600.75 2,600.75(0.33%) , ICICI Bank : 1,363.50 1,363.50(-1.35%) , Infosys : 1,528.85 1,528.85(3.86%) , ITC : 415.85 415.85(0.73%) , Kotak Mah. Bank : 2,225.05 2,225.05(1.32%) , Larsen & Toubro : 3,918.00 3,918.00(0.79%) , M & M : 3,622.70 3,622.70(0.08%) , Maruti Suzuki : 16,383.30 16,383.30(-0.04%) , NTPC : 342.60 342.60(0.15%) , Power Grid Corpn : 289.65 289.65(0.31%) , Reliance Industr : 1,448.05 1,448.05(-1.17%) , SBI : 911.45 911.45(0.37%) , Sun Pharma.Inds. : 1,689.00 1,689.00(-0.08%) , Tata Motors : 405.85 405.85(0.98%) , Tata Steel : 174.10 174.10(0.75%) , TCS : 3,074.65 3,074.65(2.24%) , Tech Mahindra : 1,462.85 1,462.85(1.00%) , Titan Company : 3,771.85 3,771.85(1.15%) , Trent : 4,784.35 4,784.35(-0.12%) , UltraTech Cem. : 12,142.75 12,142.75(-1.65%) ,

Nifty 50 : 25,891.40 22.80(0.09%) , Adani Enterp. : 2,545.80 -4.10(-0.16%) , Adani Ports : 1,453.10 -20.40(-1.38%) , Apollo Hospitals : 7,968.50 -43.50(-0.54%) , Asian Paints : 2,502.40 -2.20(-0.09%) , Axis Bank : 1,258.80 21.50(1.74%) , Bajaj Auto : 9,047.00 -71.00(-0.78%) , Bajaj Finance : 1,094.15 7.65(0.70%) , Bajaj Finserv : 2,176.60 7.50(0.35%) , Bharat Electron : 418.65 0.95(0.23%) , Bharti Airtel : 2,007.90 -35.60(-1.74%) , Cipla : 1,645.10 -18.50(-1.11%) , Coal India : 392.65 1.55(0.40%) , Dr Reddy's Labs : 1,279.40 -9.30(-0.72%) , Eicher Motors : 6,884.50 -134.00(-1.91%) , Eternal Ltd : 328.35 -9.75(-2.88%) , Grasim Inds : 2,864.60 -6.10(-0.21%) , HCL Technologies : 1,523.90 37.90(2.55%) , HDFC Bank : 1,008.80 1.10(0.11%) , HDFC Life Insur. : 743.65 -0.05(-0.01%) , Hind. Unilever : 2,601.60 9.90(0.38%) , Hindalco Inds. : 792.40 7.45(0.95%) , ICICI Bank : 1,363.70 -18.30(-1.32%) , Infosys : 1,528.50 56.10(3.81%) , Interglobe Aviat : 5,789.00 -124.00(-2.10%) , ITC : 415.95 3.10(0.75%) , Jio Financial : 309.05 -2.75(-0.88%) , JSW Steel : 1,138.20 -14.30(-1.24%) , Kotak Mah. Bank : 2,225.60 28.60(1.30%) , Larsen & Toubro : 3,918.70 30.50(0.78%) , M & M : 3,623.60 2.40(0.07%) , Maruti Suzuki : 16,393.00 -3.00(-0.02%) , Max Healthcare : 1,211.00 7.00(0.58%) , Nestle India : 1,272.80 -14.50(-1.13%) , NTPC : 342.65 0.65(0.19%) , O N G C : 252.31 4.19(1.69%) , Power Grid Corpn : 289.65 1.05(0.36%) , Reliance Industr : 1,448.40 -16.80(-1.15%) , SBI : 911.55 3.70(0.41%) , SBI Life Insuran : 1,852.70 11.70(0.64%) , Shriram Finance : 709.65 14.40(2.07%) , Sun Pharma.Inds. : 1,689.90 -0.60(-0.04%) , Tata Consumer : 1,161.00 -13.60(-1.16%) , Tata Steel : 174.16 1.38(0.80%) , TCS : 3,073.20 66.50(2.21%) , Tech Mahindra : 1,463.40 14.70(1.01%) , Titan Company : 3,772.30 43.30(1.16%) , Trent : 4,783.30 -7.80(-0.16%) , UltraTech Cem. : 12,145.00 -197.00(-1.60%) , Wipro : 244.30 2.94(1.22%) , Thursday, October 23, 2025

Home >> Markets >> Equities >> News - News Details
DAILY MARKET TRACKER
MARKET ANALYSIS
NEWS
CORPORATE INFO
CORPORATE ACTIONS
OTHER MARKETS
Hot Pursuit
23-Oct-2025     12:58
Biocon's biologics arm gets Health Canada approval for monoclonal antibody drug Yesintek

Yesintek is ustekinumab injection and Yesintek I.V. is ustekinumab for injection, solution for intravenous infusion. These drugs are biosimilars of Stelara (ustekinumab injection) and Stelara I.V. (ustekinumab for injection, solution for intravenous infusion).

The Health Canada approval was based on a comprehensive data package, confirming that YESINTEK is highly similar to Stelara with no clinically meaningful differences in efficacy, safety and immunogenicity.

The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October.

YESINTEK and YESINTEK I.V. are indicated for the treatment of moderate to severe plaque psoriasis in adult patients and in pediatric patients (6-17 years of age), active psoriatic arthritis in adults, moderately to severely active Crohn's disease and ulcerative colitis in adults'a range of debilitating autoimmune conditions that affect thousands of Canadians.

Shreehas Tambe, CEO & managing director, Biocon Biologics, said: Health Canada's approval of Yesintek marks a significant milestone in our mission to expand global access to high-quality biosimilars.

Building on our successful U.S. launch, this approval strengthens our presence in North America and enhances our immunology portfolio with a more affordable treatment option for Canadian patients living with chronic autoimmune conditions.

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

In its latest financial results, Biocon reported a 95.2% decline in consolidated net profit to Rs 31.40 crore despite a 15.8% jump in net sales to Rs 3,910.10 crore in Q1 FY26 compared to Q1 FY25.

The scrip rose 0.41% to currently trade at Rs 365.70 on the BSE.

Powered by Capital Market - Live News